at one of the leading cancer research centers in the United States showing that the Company's lead drug candidate Escozine(R) caused up to 95 percent Specific Induced Apoptosis (SIA) in various types of Leukemia cancer cells. Such a result is significant not only to the Company's ongoing clinical research, but could have tremendous effects on cancer treatments worldwide.
Do your research, take your position, turn off the noise.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.